Shots:

• ImmunoGen to receive $13M up front for initial targets, $32.5M in exercise fees if Lilly licenses the full number of targets, ~$1.7B in target program exercise fees & milestone upon achievement of pre-specified development, regulatory & commercial milestones along with royalties. Lilly will select a pre-specified no. of additional targets
• Eli Lilly gets exclusive rights to research, develop & commercialize ADCs directed to targets based on ImmunoGen's novel camptothecin technology. ImmunoGen obtains the full rights to the camptothecin platform for all targets
• The agreement will use ImmunoGen's camptothecin technology to develop ADCs. Lilly will be responsible for all costs related to R&D

 Ref: ImmunoGen | Image: ImmunoGen